Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF in Pediatric Sepsis-induced MODS
NCT05266001Phase 3Completed
- Sponsor
- Nationwide Children's Hospital
- Start
- Jun 2022
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple organ dysfunction syndrome (MODS) comparing GM-CSF with Placebo (2 arms). Primary endpoint: Pediatric Logistic Organ Dysfunction-2 score at 28 days. Started Jun 2022; status: completed.
02
Drugs
sargramostim
03
Conditions
multiple organ dysfunction syndrome (MODS)
Beyond the preview
Go deeper on NCT05266001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266001.